It is concluded that metformin use is associated with lower ALT and AST levels in diabetic patients with suspected non-alcoholic fatty liver disease (NAFLD), suggesting a possible beneficial relationship. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.